期刊文献+

CIK联合化疗治疗晚期食管癌的疗效观察 被引量:3

Clinical effects on chemotherapy combined with CIK for patients with advanced oesophageal carcinoma
下载PDF
导出
摘要 目的:探讨CIK联合FP化疗治疗进展期食管癌的可行性,安全性及近期疗效。方法:观察组21例采用CIK联合FP方案:DDP 30 mg/m^2,静滴,第1-3 d,5-FU500 mg/m^2,静滴,第1-5 d,化疗前抽血行CIK细胞培养,12-14 d培养结束后回输,21 d为1周期。对照组25例采用FP方案同观察组。观察两组患者疗效,生存质量,免疫功能的变化。结果:两组46例患者均完成治疗计划。两组均无CR病例。对照组PR 8例,SD 8例,PD 9例,有效率32%,临床获益率64%,CIK联合FP观察组,PR 10例,SD 7例,PD 4例,有效率47.6%,临床获益率80.95%。两组近期疗效有统计学差异(P〈0.05)。疗程结束后2周,观察组治疗前后患者外周血中淋巴细胞表型进行分析显示,患者免疫功能状态较治疗前有明显改善。结论:CIK联合化疗治疗食管癌是一种安全可行,有效的治疗模式。 Objective: To explore the feasibility,safety,and efficacy of CIK combinated chemotherapy in the treatment of advanced oesophageal carcinoma.Methods: 21 patients were treated with CIK combined with FP regimen,5-Fu 500 mg/m^2,iv,1-5 d;DDP 30 mg/m^2,iv,1-3 d;CIK cells were induced and then were transfused back to the patients.The changes of tumor,life quality,and immunity indexes were observed.Control group only were treated with FP regimen.Results: All patients completed the therapy regimen successfully.None complete remission was obsevered in the two groups.While in the control group,the clinical benefical rate was 64%,with PR 32%. In the study group,the clinical benefical rate was 80.95%,with PR 47.6%.It has significant differences between the two groups in terms of clinical benefical rate,life quality and immunity indexes.Conclusion: CIK combinated with FP chemotherapy regimen is a safe and feasible approach to advanced oesophageal carcinoma.
出处 《河南医学研究》 CAS 2010年第3期315-317,320,共4页 Henan Medical Research
关键词 食管癌 CIK 化疗 oesophageal carcinoma CIK chemotherapy
  • 相关文献

参考文献14

  • 1Compagnin C,Mognato M,Celotti L,et al.Cell proliferation and cell cycle alterations in oesophageal p53-mutated cancer cells treated with cisplatin in combination with photodynamic therapy[J].Cell Prolif,2010,43(3):262-274.
  • 2Weng DS,Zhou J,Zhou QM,et al.Minimally Invasive Treatment Combined With Cytokineinduced Killer Cells Therapy Lower the Short-term Recurrence Rates of Hepatocellular Carcinomas[J].J Immunother,2008,31(1):63-71.
  • 3Kolitz JE,Mertelsmann R.The immunotherapy of human cancer with interleukin-2:present status and future directions[J].Cancer Invest,1991,9(5):529-542.
  • 4Meseri A,Delwail A,Brizaard J,et al.Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukeamia treated with a-interferon[J].Brit J Heamatol,1993,83(2):218-225.
  • 5Fremond CM,Yeremeev V,Nicolle DM,et al.Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88[J].J Clin Invest,2004,114(12):1790-1799.
  • 6Dohlsten M,Abrahmsen L,Bjork P,et al.Monoclonal antibody super antigen fusion proteins:tumor specific agents for T cell based tumortherapy[J].Pro Natl Acad Sci USA,1994,91(21):8945 -8949.
  • 7Tiedemann RE,Urban RJ,Strominger JL,et al.Isolation of HLA-DR1(staphylococcal enterotoxin A)trimers in solution[J].Proc Natl Acad Sci,1995,92(26):12156-12159.
  • 8Ramakrishnan R,As sudani D,Nagaraj S,et al.Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice[J].J Clin Invest,2010,120(4):1111-1124.
  • 9Antonia SJ,M irza N,Fricke I,et al.Combination of p53 cancer vaccine with chemotherapy in patients with extensivestage small cell lung cancer[J].Clin Cancer Res,2006,12(N3Pt1):878-887.
  • 10Arlen PM,Gulley JL,Parker C,et al.A randomized phase Ⅱ study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer[J].Clin Cancer Res,2006,12(4):1260-1269.

同被引文献52

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部